MARKET

RARE

RARE

Ultragenyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

81.95
-4.31
-5.00%
After Hours: 81.95 0 0.00% 16:00 07/13 EDT
OPEN
87.17
PREV CLOSE
86.26
HIGH
87.80
LOW
81.74
VOLUME
474.93K
TURNOVER
--
52 WEEK HIGH
91.77
52 WEEK LOW
31.99
MARKET CAP
4.90B
P/E (TTM)
-11.1394
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RARE stock price target is 82.00 with a high estimate of 94.00 and a low estimate of 57.00.

EPS

RARE News

More
ClearBridge Aggressive Growth Strategy Portfolio Manager Commentary Q2 2020
Seeking Alpha - Article · 1d ago
XBI: Not Everybody Can Be A Hero
Seeking Alpha - Article · 5d ago
Corcept's Phase 3 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/05 10:40
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $91
Canaccord Genuity analyst Arlinda Lee maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $85 to $91.
Benzinga · 07/02 14:43
Ultragenyx (RARE) Looks Good: Stock Adds 8.2% in Session
Zacks · 07/02 13:41
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 07/02 12:21
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.
Zacks · 07/01 16:11
Credit Suisse Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $64
Credit Suisse maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and raises the price target from $60 to $64.
Benzinga · 07/01 14:05

Industry

Biotechnology & Medical Research
-1.52%
Pharmaceuticals & Medical Research
+0.01%

Hot Stocks

Symbol
Price
%Change

About RARE

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
More

Webull offers kinds of Ultragenyx Pharmaceutical Inc stock information, including NASDAQ:RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.